Cover Image

Effect of the stereospecific vs non-stereospecific analytical method on the drug bioequivalence: case study of bicalutamide tablets

Varad R. Pradhan, M. V. Rathnam*, Siddheshwar Patankar, S. B. Dharap, Ashutosh Pudage

Abstract


Stereoselectivity is an important consideration in the risk assessment of pharmaceuticals. Chiral separation, enantioselective analysis and asymmetric synthesis technology is rapidly improving, principally driven by the pharmaceutical industry. Therefore it may be reasonable to expect manufacturers to carry out toxicological testing using the individual pure enantiomers of chiral compounds and to justify whenever chiral products are manufactured as the racemates. There are numerous examples in the scientific literature of individual enantiomers displaying different biological effects. Differential metabolism of chiral compounds has been demonstrated for a wide variety of pharmaceuticals; however, differential effects can also result from other factors. The most obvious difference between enantiomers is intrinsic toxicological effect (pharmacodynamics), where one enantiomer has a different mode of action from another or may even be non-toxic. A better understanding of when stereoselective pharmacokinetic and bio-availability investigations are needed or not needed can be obtained by exploring the relationships that exist between the separate pharmacokinetic parameters of enantiomers and racemates. The present work throws light on one of the most important aspect in bio-availability studies, i.e. the effect of the analytical method (stereospecific vs. non- stereospecific) on the statistical power of the bio-availability and bio-equivalence trials. Bicalutamide (BCT) is a non-steroidal antiandrogen used for the treatment of prostate cancer. BCT as such is a racemic mixture, but most of its pharmacological activity is attributed to its R enantiomer. 50mg dose of BCT was monitored using stereospecific as well as non-stereospecific liquid chromatography tandem mass spectrometric analytical methods. The data revealed that the absolute bio-availability of Bicalutamide tablets is primarily due to R enantiomer. S enatiomer contribution to the bio-availability is negligible, due to its rapid clearance. Interestingly, data revealed that pharmacokinetic parameters for Bicalutamide enantiomers do not follow dose proportion kinetics. Based on the above facts, it may be courageous enough, to state that single enantiomer drug based on R enantiomer for Bicalutamide is promising.

Keywords


Bicalutamide; Chiral; LC-MS/MS; Human Plasma; Enantiomers; Racemates; Stereospecific; Non-Stereospecific; Analytical method; Bioequivalence.

Full Text:

PDF

References


Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Endocr. Relat. Cancer, 2005, 12, 631.

Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, Lee SJ, Jung C, Jimenez JA, Gardner TA, Jeng MH, Kao C, Cancer Res, 2005, 65, 1941.

Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS, Clin. Cancer Res, 2004, 10, 440.

Jemal A, Thomas H, Murray T, Thun M, CA Cancer J. Clin, 2002, 52, 23.

Brinkmann AO, Trapman, J. Nat. Med. 2000, 6, 628.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP, Nat. Genet. 1995, 9, 401.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SPN, Engl. J. Med, 1995, 332, 1393.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ, CA Cancer J. Clin, 2003, 53, 5.

Brawer, M. K. Rev. Urol. 2003, 5, S29.

Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, Van-Rooij HCJ, Trapman J, Brinkmann AO, Biochem. Biophys. Res. Commun, 1990, 17, 534.

Benetl JM, Tilley WD, J. Endocrinol. 1996, 151, 1.

Ford OH, Gregory CW, Kim D, Smitherman AB, Mohler JL, J. Urol. 2003, 170, 1817.

Golias C, Iliadis I, Peschos D, Charalabopoulos K, Exp. Oncol, 2009, 31, 3.

Kimura K, Markowski M, Bowen C, Gelmann EP, Cancer Res, 2001, 61, 5611.

Gao W, Bohl CE, Dalton JT, Chem. Rev, 2005, 105, 3352.

Mohler ML, Nair VA, Hwang DJ, Rakov IM, Patil R, Miller DD, Expert Opin. Ther. Pat, 2005, 15, 1565.

Ishak KG, Zimmerman HJ, Semin. Liver Dis. 1987, 7, 230.

Gao W, Dalton JT, Drug Discovery Today, 2007, 12, 241.

Gao W, Kim J, Dalton JT, Pharm. Res, 2006, 23, 1641.

Heidenreich A, Aus G, Joniau S, for the European Association of Urology. EAU guidelines on prostate cancer. Eur Urol, 2008, 53, 68–80.

Furr BJ, Eur Urol, 1996, 29(Suppl 2), 83–95.

Wirth MP, Hakenberg OW, Froehner M. Front Radiat Ther Oncol, 2008, 41, 39–48.

Wirth MP, See WA, McLeod DG, J Urol, 2004, 172, 1865–1870.

Mukherjee A, Kirkovsky L, Yao XT, Enantioselective binding of Casodex to the androgen receptor. Xenobiotica, 1996, 26, 117–122.

McKillop D, Boyle GW, Cockshott ID, Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica, 1993, 23, 1241–1253.

Boyle GW, McKillop D, Phillips PJ, et al. Metabolism of Casodex in laboratory animals. Xenobiotica, 1993, 23, 781–798.

Cockshott ID, Bicalutamide: Clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004; 43:855–878.

Pradhan VR, Pudage A, Patankar S, Sawant S, Rathnam MV, Int. J. of Bioassays, 2013, 02 (09), 1210-1222.

Online document CDER (Center for Drug Evaluation and Research), Guidance for Industry: Bioanalytical Method Validation, US FDA, 2001.

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf

Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), 1996.

Yadav M, Shrivastav PS, Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research Bioanalysis, 2011, 3, 1007-1024.




DOI: http://dx.doi.org/10.21746/ijbio.2015.04.007

Refbacks

  • There are currently no refbacks.




Copyright (c) 2015 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.